RxDoctor Payments Data

Kim Schurman, MD

Internal Medicine · Fort Myers, FLNPI 1881884419

Payments from drug & device makers

$7,275in general payments, 2019–2025

Across 399 payments — averaging $18.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$887
  • AstraZeneca$763
  • Amgen$604
  • Novo Nordisk$533
  • AbbVie$531
  • Amarin Pharma, Inc.$504
  • plus $3K from 43 others

What the payments were for

  • Food & beverage$7,21599%
  • Gifts$591%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,275 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$130,555
Medicare patients
237
Services billed
2,775

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban101$84,874
XareltoRivaroxaban27$32,518
OzempicSemaglutide24$31,942
JanuviaSitagliptin Phosphate23$28,785
JardianceEmpagliflozin13$11,462
RybelsusSemaglutide11$9,688
Repatha SureclickEvolocumab12$7,856
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$2,783
Atorvastatin Calcium343$2,723
Levothyroxine Sodium330$2,722
Losartan Potassium277$2,488
SynthroidLevothyroxine Sodium35$2,314
Gabapentin130$2,144
Rosuvastatin Calcium260$2,122
Omeprazole148$1,808

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$429$84,874101 claims
Novo NordiskOzempic, Rybelsus$533$41,63035 claims
Johnson & JohnsonXarelto$120$32,51827 claims
MerckJanuvia$146$28,78523 claims
Boehringer IngelheimJardiance$16$11,46213 claims
AbbVieSynthroid$531$2,31435 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Fort Myers

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →